Soluble type II transforming growth factor-β (TGF-β) receptor inhibits TGF-β signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation

Clinical Cancer Research

Volumn 7, Issue 9, 2001, Pages 2931-2940

  Rowland Goldsmith, Melissa A ^a   Maruyama, Haruhisa ^a   Kusama, Toshiyuki ^a   Ralli, Sonia ^a   Korc, Murray ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ARTICLE; CANCER INVASION; CANCER SURVIVAL; GROWTH INHIBITION; HUMAN; HUMAN CELL; PANCREAS CANCER; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; CELL DIVISION; CELL MOVEMENT; FEMALE; GENE EXPRESSION; GENETIC VECTORS; HUMANS; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SOLUBILITY; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0034803035     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. TGF-β signal transduction
2. Pancreatic carcinoma
3. K-ras and p53 gene mutations in pancreatic cancer: Ductal and nonductal tumors progress through different genetic lesions
4. Role of growth factors in pancreatic cancer
5. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1
6. Disruption of the antiproliferative TGF-β signaling pathways in human pancreatic cancer cells
7. Frequent codeletion of p16/MTS1 and p15/MTS2 and genetic alterations in p16/MTS1 in pancreatic tumors
8. Enhanced expression of transforming growth factor β isoforms in pancreatic cancer correlates with decreased survival
9. Growth inhibition of human pancreatic carcinoma cells by transforming growth factor β-1
10. Up-regulation of transforming growth factor (TGF)-β receptors by TGF-β1 in COLO-357 cells
11. Attenuated ALK5 receptor expression in human pancreatic cancer: Correlation with resistance to growth inhibition
12. Ligand induced upregulation of the type II transforming growth factor (TGF-β) receptor enhances TGF-β responsiveness in COLO-357 cells
13. Smad6 suppresses TGF-β-induced growth inhibition in COLO-357 pancreatic cancer cells and is overexpressed in pancreatic cancer
14. The TGF-β signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer
15. The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer
16. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
17. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor α
18. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays
19. Rapid colorimetric assay for cell viability: Application to the quantitation of cytotoxic and growth inhibitory lymphokines
20. A rapid in vitro assay for quantitating the invasive potential of tumor cells
21. Detection and localization of Mip-3α/LARC/Exodus, a macrophage proinflammatory chemokine, and its CCR6 receptor in human pancreatic cancer
22. Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: Immunohistochemical study
23. Overexpression of Smad2 and colocalization with TGF-β1 in human pancreatic cancer
24. The soluble exoplasmic domain of the type II transforming growth factor (TGF)-β receptor. A heterogeneously glycosylated protein with high affinity and selectivity for TGF-β ligands
25. Tumorigenicity of mouse thymoma is suppressed by soluble type II transforming growth factor β receptor therapy
26. Evidence that smad2 is a tumor suppressor implicated in the control of cellular invasion
27. Inactivation of the type II receptor reveals two receptor pathways for the diverse TGF-β activities
28. Extracellular matrix-associated transforming growth factor-β: Role in cancer cell growth and invasion
29. Transforming growth factor β1 stimulates contrasting responses in metastatic versus primary mouse prostate cancer-derived cell lines in vitro
30. The plasminogen activation system in tumor growth, invasion, and metastasis
31. DPC4/SMAD4 mediated tumor suppression of colon carcinoma cells is associated with reduced urokinase expression
32. TGFβ signaling is necessary for carcinoma cell invasiveness and metastasis
33. Antisense oligonucleotides specific for transforming growth factor β2 inhibit the growth of malignant mesothelioma both in vitro and in vivo
34. Excessive production of transforming growth-factor β 1 can play an important role in the development of tumorigenesis by its action for angiogenesis: Validity of neutralizing antibodies to block tumor growth
35. Transforming growth factor type β: Rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro
36. Transforming growth factor β 1-induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane
37. Influence of plasminogen activator inhibitor type I on choroidal neovascularization
38. Identification of important regions in the cytoplasmic juxtamembrane domain of type I receptor that separate signaling pathways of transforming growth factor-β
39. Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis
40. Anti-transforming growth factor (TGF)-β antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-β interactions in human breast cancer progression
41. Anti-(transforming growth factor β) antibodies with predefined specificity inhibit metastasis of highly tumorigenic human xenotransplants in nu/nu mice
42. Transforming growth factor-β: Antisense RNA-mediated inhibition affects anchorage-independent growth, tumorigenicity and tumor-infiltrating T-cells in malignant mesothelioma
43. Antisense oligonucleotide specific for transforming growth factor-β 1 inhibit both in vitro and in vivo growth of MBT-2 murine bladder cancer
44. Dominant negative mutants of transforming growth factor-β 1 inhibit the secretion of different transforming growth factor-β isoforms
45. βglycan can act as a dual modulator of TGF-β access to signaling receptors: Mapping of ligand binding and GAG attachment sites
46. A soluble transforming growth factor β type III receptor suppresses tumorigenicity and metastasis of human breast cancer MDA-MB-231 cells
47. Chimeric extracellular domain type II transforming growth factor (TGF)-β receptor fused to the Fc region of human immunoglobulin as a TGF-β antagonist
48. Transforming growth factor β is essential for spindle cell conversion of mouse skin carcinoma in vivo: Implications for tumor invasion
49. TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development